Clinical trials
Completed Phase 4 trials in Japan
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
268 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 5 |
| 2003 | 7 |
| 2004 | 17 |
| 2005 | 13 |
| 2006 | 16 |
| 2007 | 15 |
| 2008 | 11 |
| 2009 | 11 |
| 2010 | 18 |
| 2011 | 16 |
| 2012 | 14 |
| 2013 | 20 |
| 2014 | 27 |
| 2015 | 20 |
| 2016 | 18 |
| 2017 | 13 |
| 2018 | 7 |
| 2019 | 4 |
| 2020 | 3 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 268 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Astellas Pharma Inc | 17 |
| GlaxoSmithKline | 12 |
| Takeda | 12 |
| Boehringer Ingelheim | 10 |
| Novartis Pharmaceuticals | 10 |
| Sanofi | 9 |
| Takeshi Morimoto | 9 |
| Eli Lilly and Company | 8 |
| Kumamoto University | 8 |
| Janssen Pharmaceutical K.K. | 6 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetes Mellitus, Type 2 | 39 |
| Hypertension | 25 |
| Coronary Artery Disease | 21 |
| Diabetes Mellitus | 10 |
| Hypercholesterolemia | 9 |
| Cardiovascular Diseases | 8 |
| Heart Failure | 7 |
| Insulin Resistance | 7 |
| Kidney Failure, Chronic | 7 |
| Arthritis, Rheumatoid | 6 |
Trials
Showing 1 to 25 of 268. Each trial links to its page on Pharma Observatory.
168 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.